# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-279096
Filing Date
2025-11-13
Accepted
2025-11-13 08:35:02
Documents
60
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | fate-20250930.htm iXBRL | 10-Q | 2958432
2 | EX-10.1 | fate-ex10_1.htm | EX-10.1 | 41612
3 | EX-31.1 | fate-ex31_1.htm | EX-31.1 | 13164
4 | EX-31.2 | fate-ex31_2.htm | EX-31.2 | 12532
5 | EX-32.1 | fate-ex32_1.htm | EX-32.1 | 12700
| Complete submission text file | 0001193125-25-279096.txt |  | 12824064

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | fate-20250930.xsd | EX-101.SCH | 1328849
63 | EXTRACTED XBRL INSTANCE DOCUMENT | fate-20250930_htm.xml | XML | 3165903

Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 251475610
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)